Read More Pharma Industry News Why BTK inhibitor resistance is becoming a growth driver for Cellectar Biosciences, Inc. (NASDAQ: CLRB) Can Cellectar Biosciences, Inc. turn BTK inhibitor resistance into an opportunity? Explore what iopofosine I 131 means for WM strategy. bySoujanya RaviMay 8, 2026